(completed weeks/months/years)
Vaccines Comments
Birth BCG
Hep-B 1
Administer these vaccines to all newborns before hospital
6 weeks DTwP 1
Hep-B 2
Hib 1
Rotavirus 1

DTaP vaccine/combinations should preferably be avoided for the primary series

DTaP vaccine/combinations should be preferred in certain specific circumstances/conditions only

No need of repeating/giving additional doses of whole-cell pertussis (wP) vaccine to a child who has earlier completed their primary schedule with acellular pertussis (aP) vaccine-containing products


All doses of IPV may be replaced with OPV if administration of the former is unfeasible

Additional doses of OPV on all supplementary immunization activities (SIAs)

Two doses of IPV instead of 3 for primary series if started at 8 weeks, and 8 weeks interval between the doses

No child should leave the facility without polio immunization (IPV or OPV), if indicated by the schedule

See footnotes under figure titled IAP recommended immunization schedule (with range) for recommendations on intradermal IPV


2 doses of RV1 and 3 doses of RV5 & RV 116E

RV1 should be employed in 10 & 14 week schedule,10 & 14 week schedule of RV1 is found to be more immunogenic than 6 & 10 week schedule

10 weeks DTwP 2
Hib 2
Rotavirus 2
If RV1 is chosen, the first dose should be given at 10 weeks
14 weeks DTwP 3
Hib 3
Rotavirus 3

Only 2 doses of RV1 are recommended.

If RV1 is chosen, the 2 nd dose should be given at 14 weeks

6 months OPV 1
Hep-B 3
Hepatitis-B: The final (3rd or 4th ) dose in the HepB vaccine series should be administered no earlier than age 24 weeks and at least 16 weeks after the first dose.
9 months OPV 2

Measles-containing vaccine ideally should not be administered before completing 270 days or 9 months of life;

The 2 nd dose must follow in 2 nd year of life;

No need to give stand-alone measles vaccine

9-12 months Typhoid Conjugate Vaccine

Currently, two typhoid conjugate vaccines, Typbar-TCV® and PedaTyph® available in Indian market; either can be used

An interval of at least 4 weeks with the MMR vaccine should be maintained while administering this vaccine

12 months Hep-A 1 Hepatitis A:

Single dose for live attenuated H2-strain Hep-A vaccine

Two doses for all inactivated Hep-A vaccines are recommended

15 months MMR 2
Varicella 1
PCV booster

The 2 nd dose must follow in 2 nd year of life

However, it can be given at anytime 4-8 weeks after the 1 st dose


The risk of breakthrough varicella is lower if given 15 months onwards

16 to 18 months DTwP B1/DTaP B1
Hib B1

The first booster (4 th th dose) may be administered as early as age 12 months, provided at least 6 months have elapsed since the third dose.


1st & 2 nd boosters should preferably be of DTwP

Considering a higher reactogenicity of DTwP,DTaP can be considered for the boosters

18 months Hep-A 2 Hepatitis A:

2 nd dose for inactivated vaccines only

2 years Booster of Typhoid
Conjugate Vaccine

A booster dose of Typhoid conjugate vaccine (TCV), if primary dose is given at 9-12 months

A dose of Typhoid Vi-polysaccharide (Vi-PS) vaccine can be given if conjugate vaccine is not available or feasible;

Revaccination every 3 years with Vi-polysaccharide vaccine

Typhoid conjugate vaccine should be preferred over Vi- PS vaccine

4 to 6 years DTwP B2/DTaP B2
Varicella 2

the 2 nd dose can be given at anytime 3 months after the 1 st dose.


the 3rd dose is recommended at 4-6 years of age.

10 to 12 years Tdap/Td
Tdap: is preferred to Td followed by Td every 10 years

Only 2 doses of either of the two HPV vaccines for adolescent/preadolescent girls aged 9-14 years;

For girls 15 years and older, and immunocompromised individuals 3 doses are recommended

For two-dose schedule, the minimum interval between doses should be 6 months.

For 3 dose schedule, the doses can be administered at 0, 1-2 (depending on brand) and 6 months

II. IAP recommended vaccines for High-risk* children (Vaccines under special circumstances) #:

1-Influenza Vaccine

2-Meningococcal Vaccine

3-Japanese Encephalitis Vaccine

4-Cholera Vaccine

5-Rabies Vaccine

6-Yellow Fever Vaccine

7-Pneumococcal Polysaccharide vaccine (PPSV 23)

* High-risk category of children:

Congenital or acquired immunodeficiency (including HIV infection),

Chronic cardiac, pulmonary (including asthma if treated with prolonged high-dose oral corticosteroids), hematologic, renal (including nephrotic syndrome), liver disease and diabetes mellitus

Children on long term steroids, salicylates, immunosuppressive or radiation therapy

Diabetes mellitus, Cerebrospinal fluid leak, Cochlear implant, Malignancies,

Children with functional/ anatomic asplenia/ hyposplenia

During disease outbreaks

Laboratory personnel and healthcare workers


Children having pets in home

Children perceived with higher threat of being bitten by dogs such as hostellers, risk of stray dog menace while going outdoor.

# For details see footnotes under figure titled 'IAP recommended immunization schedule (with range)'